Sporet levering verden over | Forventet 9–14 hverdage

Din kurv

Din indkøbskurv er tom

Begynd at browse

Gratis fragt på ordrer over €500.

Subtotal€0
Gå til betaling
RestitutionTidlig klinisk

ARA290

Publiceret forskning og dokumentationsgrundlag

ARA290 (cibinetide) is an 11-amino-acid non-erythropoietic peptide engineered from the helix B domain of erythropoietin, designed to activate the innate repair receptor (an EPO receptor/CD131 heteromer) without stimulating erythropoiesis. Of the compounds in this category it has the most developed human evidence: multiple completed randomised placebo-controlled phase 2 trials in sarcoidosis-associated small fibre neuropathy, type 2 diabetes with painful neuropathy, and diabetic macular edema. Results have generally shown improvement in patient-reported neuropathic symptoms and in corneal nerve fibre measures, but no regulatory approval has followed and no phase 3 programme has reported.

Kort fortalt
  • ARA290 er et syntetisk peptid afledt af erythropoietin.
  • Humane forsøg rapporterede forbedringer i neuropatisymptomer og corneale nerver.
  • Ingen fase 3-forsøg er rapporteret og ingen studier testede muskelskeletal bedring.

17 studier · 7 siden 2023 · nyeste 2026

Undersøgelser citeret
17
Publiceret 2023+
7
Nyeste artikel
2026
Sidst gennemgået
okt. 2026

Tilbagevendende temaer i litteraturen

  • innate repair receptor / EPOR-CD131 heteroreceptor
  • small fibre neuropathy and corneal nerve fibre density
  • neuropathic pain and allodynia
  • anti-inflammatory and monocyte modulation
  • non-erythropoietic tissue protection
  • metabolic control and islet protection

Stofidentifikatorer

CAS
1208243-50-8
PubChem
91810664

Kemisk identitet

Hvad ARA290 er, kemisk.

Molekylformel
C51H84N16O21
Molekylvægt
1257.3 g/mol
CAS-nummer
1208243-50-8
PubChem CID
91810664
Også skrevet som

Cibinetide, ARA-290, pHBSP peptide

Disse tal stammer fra PubChem-posten for denne forbindelse og beskriver den frie base. Lyofiliseret peptid leveres normalt som et acetat- eller trifluoroacetatsalt og indeholder restvand, så massen af pulver i et hætteglas er ikke den samme mængde, som molekylvægten ovenfor ville antyde. Kromatografisk renhed på et analysecertifikat løser heller ikke den forskel — Sådan læses et analysecertifikat forklarer hvorfor.

Evidensen

17 offentliggjorte studier.

Sorteret efter styrken i studiedesignet og derefter efter nyhed. Hver post linker til sin kildepost, så fundet kan kontrolleres mod artiklen i stedet for at tages på vores ord.

  1. 01Humant klinisk2020

    A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema

    Lois N, et al. · J Clin Med · phase 2 trial; treatment-naive patients with central retinal thickness above 400 um, self-administered cibinetide 4 mg/day subcutaneously for 12 weeks

    The trial measured change from baseline to week 12 in best corrected visual acuity, central retinal thickness and central retinal sensitivity in diabetic macular edema.

  2. 02Humant klinisk2017

    Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain

    Culver DA, et al. · Invest Ophthalmol Vis Sci · phase 2b, 28-day, multicentre randomised trial; 64 subjects with sarcoidosis-associated small nerve fibre loss and neuropathic pain, corneal confocal microscopy endpoints

    The trial assessed cibinetide's effect on corneal nerve fibre area and regenerating GAP-43-positive intraepidermal fibres as surrogate disease-modification endpoints alongside pain severity. This is the largest randomised dataset for the compound.

  3. 03Humant klinisk2015

    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

    Brines M, et al. · Mol Med · phase 2 controlled clinical trial in subjects with type 2 diabetes and painful neuropathy

    ARA 290 was associated with improvements in metabolic control and in neuropathic symptoms in patients with type 2 diabetes, without the hematopoietic effects that limit erythropoietin.

  4. 04Humant klinisk2015

    Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.

    Cerit H, et al. · Eur Neuropsychopharmacol · double-blind placebo-controlled RCT, healthy volunteers, n=36, single administration, assessed after 1 week

    ARA290-treated participants showed lower fusiform-gyrus responses to happy faces, faster categorisation of positive vs negative words and increased attention to positive pictures; mood and affective symptoms were unchanged, and the authors concluded the profile did not clearly support an antidepressant-like effect.

  5. 05Humant klinisk2013

    ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

    Dahan A, et al. · Mol Med · randomised controlled trial in sarcoidosis patients with small nerve fibre loss and damage

    ARA 290 improved patient-reported symptoms of small nerve fibre loss and increased corneal nerve fibre density relative to control.

  6. 06Humant klinisk2012

    Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

    Heij L, et al. · Mol Med · double-blind, placebo-controlled exploratory trial; 22 patients with sarcoidosis and small fibre neuropathy symptoms, intravenous dosing three times weekly

    The pilot trial reported on the safety of ARA 290 and its effect on small fibre neuropathy symptoms in sarcoidosis, following preclinical evidence of reduced allodynia.

  7. 07Dyr in vivo2026

    Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice

    Alasousi D, et al. · Neurobiol Dis · male db/db mice and db/m lean controls on a touchscreen operant platform (pairwise visual discrimination and reversal learning), with glucose and insulin tolerance testing, flow cytometry and RNA-seq; ARA 290 treatment arm

    Db/db mice showed intact associative learning but impaired cognitive flexibility during reversal learning. ARA 290 treatment improved insulin sensitivity and altered circulating immune cell populations in these mice.

  8. 08Dyr in vivo2025

    ARA290 Attenuates Apical Periodontitis via SIRT1/NF-kappaB/IL-1beta Pathway Modulation

    Wang Y, et al. · Int Dent J · in vivo apical periodontitis models with macrophage pro-inflammatory response assays

    ARA290 reduced macrophage pro-inflammatory responses in apical periodontitis, with the protective effect attributed to modulation of SIRT1/NF-kappaB/IL-1beta signalling in periapical lesions.

  9. 09Dyr in vivo2025

    ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury

    Liu G, et al. · Eur J Pharmacol · rat sciatic nerve crush injury with Schwann cell analysis

    Both erythropoietin and ARA290 inhibited the early inflammatory response and promoted functional recovery after sciatic nerve crush in rats, with suppression of NLRP3 inflammasome activation in Schwann cells.

  10. 10Dyr in vivo2024

    Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the beta-common receptor in mice with cerebral ischemic stroke

    Wang RL, et al. · CNS Neurosci Ther · male C57BL/6J mice undergoing middle cerebral artery occlusion and reperfusion; neurological function tests, TTC staining and apoptosis immunofluorescence

    ARA290 reduced cerebral infarct volume and neuronal apoptosis and improved neurological scores after middle cerebral artery occlusion, with the effect dependent on the beta-common receptor.

  11. 11Dyr in vivo2022

    A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan

    Winicki NM, et al. · Front Cardiovasc Med · aged rodent model of age-associated cardiac inflammation and functional decline treated with ARA290

    ARA290 reduced cardiac inflammation and fibrosis, attenuated age-associated declines in heart function and prolonged healthspan in the treated animals.

  12. 12Dyr in vivo2018

    Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.

    Bitto A, et al. · Biochim Biophys Acta Mol Basis Dis · db/db genetically diabetic mouse incisional wound model vs wild-type

    In diabetic mice, cibinetide improved wound VEGF, phospho-Akt, phospho-eNOS and nitrite/nitrate, reduced malondialdehyde, and improved re-epithelialisation, angiogenesis, wound breaking strength and time to closure compared with vehicle.

  13. 13Dyr in vivo2011

    ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and beta-common receptor knockout mice

    Swartjes M, et al. · Anesthesiology · spared nerve injury model of neuropathic pain in rats and in mice lacking the beta-common receptor

    ARA290 produced long-term relief of tactile and cold allodynia in rats, and the absence of effect in beta-common receptor knockout mice established that the receptor complex mediates the analgesic action. This is the foundational mechanism paper.

  14. 14In vitro2025

    Mechanisms of ARA290 in counteracting cadmium-triggered neurotoxicity in PC12 cells

    Motafeghi F, et al. · Toxicol Res (Camb) · cadmium-exposed PC12 neuronal cells treated with ARA290

    ARA290 counteracted cadmium-induced neurotoxicity in PC12 cells through anti-inflammatory, anti-apoptotic and antioxidant mechanisms attributed to selective innate repair receptor activation.

  15. 15In vitro2023

    Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways

    Ghassemi-Barghi N, et al. · Inflammation · HEK-293 and ACHN renal cell lines pretreated with ARA290 (50-400 nM) before cisplatin (2.5 uM)

    ARA290 pretreatment reduced cisplatin-induced cytotoxicity, genotoxicity and oxidative stress in renal cell lines, with changes in apoptosis and inflammation pathway markers.

  16. 16In vitro2021

    Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation

    Yao M, et al. · Cell Transplant · isolated human pancreatic islets cultured with pro-inflammatory cytokines for 18 hours with or without cibinetide, plus instant blood-mediated inflammatory reaction assays

    Cibinetide preserved ATP content and protected isolated human islets under cytokine stress and modulated the instant blood-mediated inflammatory reaction relevant to intraportal islet transplantation.

  17. 17Gennemgang2025

    Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy

    Sun Y, et al. · Front Neurol · review integrating structural biology, pharmacology and translational data on four engineered erythropoietin derivatives across the traumatic brain injury timeline

    The review argued that recombinant erythropoietin limits secondary damage in animals but that its erythropoietic and thrombotic liabilities stalled clinical adoption, positioning non-erythropoietic derivatives such as ARA290 for phase-targeted use.

Begrænsninger

Hvad denne evidens ikke fastslår.

Despite more than a decade of phase 2 work, no phase 3 trial has reported and cibinetide has no regulatory approval in any jurisdiction; the human trials are small, short (28 days to 12 weeks) and concentrated in sarcoidosis and diabetic neuropathy rather than musculoskeletal recovery. There is no published human study of ARA290 for tendon, muscle or exercise-related recovery, which is how it is marketed in this category.

Almindelige spørgsmål om forskningen.

What is ARA290?

ARA290, also called cibinetide, is an 11-amino-acid peptide engineered from the helix B region of erythropoietin. It was designed to retain the tissue-protective signalling of the parent hormone without its erythropoietic activity.

What is the innate repair receptor?

The literature describes it as a heteromeric receptor complex formed from the erythropoietin receptor and the beta-common receptor subunit (CD131). It is reported as being expressed on injured or metabolically stressed tissue rather than throughout the body, which is why ARA290 is characterised as acting at sites of injury.

Does it raise haemoglobin like erythropoietin?

The design intent was specifically to avoid that. The peptide omits the erythropoietin residues associated with red blood cell production, and the published studies report no erythropoietic effect while assessing tissue-protective end points.

Fås i vores katalog

Kun til forskningsformål. Ikke til humant forbrug, diagnose, behandling eller forebyggelse af nogen tilstand. Intet på denne side er medicinsk rådgivning, og intet studie opsummeret her skal læses som en anbefaling.